Anda di halaman 1dari 6

Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.

com/viewarticle/579046_print

www.medscape.com

From The Medscape Journal of Medicine > Psychiatry

Publication Bias and the Pharmaceutical Industry: The Case of Lamotrigine in Bipolar Disorder
S. Nassir Ghaemi, MD, MPH; Arshia A. Shirzadi, DO; Megan Filkowski, BA
Published: 09/10/2008
Abstract

Publication bias, especially the lack of publication of negative treatment studies, is known to be a major problem in the medical literature. In particular, it appears that the pharmaceutical industry is
not routinely making data from negative studies available through the published scientific literature. In this paper, we review the case of studies with lamotrigine in bipolar disorder, describing
evidence of lack of efficacy in multiple mood states outside of the primary area of efficacy (prophylaxis of mood episodes). In particular, the drug has very limited, if any, efficacy in acute bipolar
depression and rapid-cycling bipolar disorder, areas in which practicing clinicians, as well as some academic leaders, have supported its use. The negative unpublished data now made available on
lamotrigine provide an important context for clinical practice and research, and also raise important scientific and public policy concerns about having access to studies showing inefficacy with
psychotropic medications.

Reader Comments on: Publication Bias and the Pharmaceutical Industry: The Case of Lamotrigine in Bipolar Disorder
See reader comments on this article and provide your own.

Readers are encouraged to respond to the author at nghaemi@tuftsmedicalcenter.org or to Peter Yellowlees, MD, Deputy Editor of The Medscape Journal of Medicine, for the editor's eyes only
or for possible publication as an actual Letter in the Medscape Journal via email: peter.yellowlees@ucdmc.ucdavis.edu

Introduction

Publication bias is known to be a major problem in the medical literature.[1-5] In general, studies with positive outcomes are more likely to be published than studies with negative outcomes.[3] This
finding also extends to the psychiatric literature.[6] Negative outcomes are here defined as randomized clinical trials (RCTs) which fail to find statistically significant benefit with an active treatment as
opposed to a control group in an adequate sample size.[7] The nonpublication of negative outcomes in RCTs has been especially reported to occur in pharmaceutical industry-funded studies, as
opposed to studies funded by governmental sources.[6,8-12] Recent controversies in varied medical disciplines have highlighted the importance of having access to such unpublished data;
previously underappreciated unpublished side effect data have led to removal of certain agents, such as the anti-inflammatory agent rofecoxib, from the US market.[13,14] Marketing of other agents,
such as gabapentin, for unproven treatment indications such as bipolar disorder despite initially unpublished studies showing absence of efficacy in that condition also has led to controversies and
even malpractice lawsuits.[15,16] A recent review of antidepressant RCTs in unipolar depression in the Food and Drug Administration (FDA) database found that almost all negative studies were
unpublished, leading to a false impression in the published literature that 93% of antidepressant RCTs had positive results; when unpublished studies were included, 51% of all RCTs were positive
and 49% were negative.[17] Thus, unpublished studies raise questions of concerns regarding both underreported risks and underreported limitations in efficacy.

In response to some of the above controversies, in 2002, the US lobbying group for the pharmaceutical industry (Pharmaceutical Research and Manufacturers Association; PhRMA) published its
"Principles on the Conduct of Clinical Trials and Communication of Clinical Trial Results" (http://www.phrma.org/publications/policy_papers/phrma_clinical_trial_registry_proposal/) and committed to
voluntarily registering all clinical trials at initiation, as well as providing access to the results of all study outcomes, positive or negative, via company-based (specific Web sites or
www.clinicalstudyresults.org) or government-based Web sites (www.clinicaltrials.gov).

In this paper, we access those Web sites of companies with agents approved for the treatment of bipolar disorder, to examine the availability of study results with negative data, and then we focus
on one of those agents with availability of negative data, lamotrigine, to examine the impact of those results on clinical interpretation of the utility of that agent in bipolar disorder.

Methods

We searched the Web sites of the following companies with FDA-approved drugs for the treatment of bipolar disorder patients: Abbott Laboratories (Depakote brand of divalproex sodium),
GlaxoSmithKline (Lamictal brand of lamotrigine), Pfizer Inc. (Geodon brand of ziprasidone), Eli Lilly and Co. (Zyprexa, Symbiaxbrands of olanzapine and olanzapine-fluoxetine combination),
Janssen Pharmaceutica (Risperdal and Risperdal Consta brand of risperidone), Bristol Myers Squibb (Abilify brand of aripiprazole), and AstraZeneca (Seroquel brand of quetiapine). We
supplemented searches of the primary company Web sites with searches of the Web sites for each drug. If no studies were identified, or if links were provided, we accessed the Web site
established by the Pharmaceutical Research Manufacturers Association (PHRMA) for clinical trial results (www.clinicaltrialresults.org) and that of the National Institutes of Health (NIH) for current
clinical trials (www.clinicaltrials.gov). Table 1 describes the studies found on their Web sites, whether they were positive or negative, and whether they were previously published. Published studies
of the same drugs were assessed by a computerized MEDLINE search of the National Library of Medicine (NLM) database (1966–2006).

Table 1. Studies of Drugs on Bipolar Disorder on Pharmaceutical Industry Web Sites

# of
studies
on
company # of # of
Web site # of previously previously
If limited data on company Type of or previously published unpublished
Ease of Web site, findings on information PHRMA published negative negative
Company Drug Web site visited navigation Results www.clinicalstudyresults.org provided Web site studies studies studies
Abbott Depakote www.abbott.com Link to No data 1 unpublished positive study Only title of 1 0 0 0
(divalproex "Depakote"; link to for Depakote ER in acute study
sodium) "Professionals"; mania[38]; no data provided.
link to "Proven No reference to 2 previously
Efficacy." No published positive studies in
further data. acute mania, [39, 40] and a
failed maintenance study.[41]

AstraZeneca Seroquel www.astrazeneca.com Link to 4 in acute NA Full protocol 6 5 0 1


(quetiapine) "AstraZeneca-US"; mania with
Link to "Products"; reported, 3 detailed
Link to "Seroquel"; positive have summary of
Link to "Healthcare been results.
professionals." No published, Mean ± SD
[42-44]
further data. and 1 length 8.6 ±
negative 1.1 pages
unpublished (range
study in acute 7-10)
mania; [45] 1
positive
published
study in acute
bipolar
depression[46]

1 de 6 25/07/2009 10:38 a.m.


Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.com/viewarticle/579046_print

Bristol-Myers Abilify www.bms.com Link to "Clinical 5 studies in No titles or data. Titles of 5 2 0 1


Squibb (aripiprazole) trials disclosure"; acute mania, studies only
Link to "Clinical bipolar No reference to 2 previously
trials registry"; depression, published positive studies.
[47,48]
Link to or mania cited
"Therapeutic by titles and
areas"; Link to listed as
"Psychiatric "Recruiting"
disorders"; with no
further
information; 3
studies cited
as "no longer
recruiting"
and 1 as
"completed."
No citations
provided.

Eli Lilly Zyprexa www.elililly.com Link to "Products"; 6 studies of NA Full protocol 10 9 1 0


(olanzapine) link to "Lilly clinical acute mania, with
trials"; link to 3 studies of detailed
"Trials results by relapse summary of
product"; link to prevention, all results.
"Zyprexa" positive Mean ± SD
published length 15.6
studies[49-57] ± 8.0 pages
(range
6-28)
Eli Lilly Symbiax www.elililly.com Link to "Products"; 1 positive NA Full protocol 1 1 0 0
(olanzapine- link to "Lilly clinical study in acute with
fluoxetine trials"; link to bipolar detailed
[58]
combination) "Trials results by depression summary of
product"; link to results.
"Symbiax" Length 16
pages

GSK Lamictal www.gsk.com Link to "Clinical See Table 2 NA See Table 2 9 2 2 5


(lamotrigine) trial register"; link
to "Lamotrigine"
Janssen Risperdal www.janssen.com Link to "Our No data No titles or data. No reference No titles or 0 4 1 0
(risperidone) products"; link to to four previously published data
"Risperdal"; link to positive studies in acute mania,
[59-62]
"Risperdal for or one previously
bipolar mania" published negative but
underpowered study in acute
bipolar depression[63]
Pfizer Geodon www.pfizer.com Link to "Medicines One efficacy 2 positive studies in acute Full protocol 2 2 0 0
(ziprasidone) and products"; link graph from 1 mania, 1 published [64] and 1 with
[65]
to "Geodon"; link published unpublished. No reference detailed
to "For healthcare study to another positive published summary of
professionals"; link provided[64] acute mania trial[66] results.
to "Clinical trial Mean ± SD
data"; link to length 7.0 ±
"Geodon for 2.0 pages
bipolar mania and (range 5-9)
mixed episodes"

Negative vs Failed Trials

Our use of the term "negative" to describe the outcomes of studies is defined as follows: In the strictest definition, this refers to a study in which the experimental drug is the same as placebo, and
in which a proven active control is more effective than placebo.[18] If an active control fails to separate from placebo, as well as the experimental drug, then this study would be seen as a "failed"
study, meaning that no conclusion could be drawn for or against efficacy, since an already proven treatment also failed to show benefit. Usually in that case, peculiar characteristics of the sample
(such as a low severity of illness leading to high placebo response) can obscure a real treatment effect.[18] In the absence of an active control group, which is often the case for FDA regulation-
oriented pharmaceutically sponsored studies, one cannot be definitively certain that equivalence of drug to placebo represents a "negative" outcome.[18] However, if the study is adequately
powered to demonstrate a modest effect size, then one can at least conclude that the study is most suggestive of lack of moderate or greater benefit.[7] In that sense, we will define studies as
negative in this report if drug is equivalent to placebo in the absence of an active control group. Further, all definitions of difference between drug and placebo will be limited to the primary outcome
measures, since secondary outcome measures are associated with inflated chance of statistically significant findings (P value below .05).[19] This limitation does not mean that secondary outcomes
are always false or unhelpful, but rather one should look for multiple measures showing robust effects, rather than isolated borderline P value-based analyses.[20]

Where the comparison is of a drug to an active control without a placebo group, usually the purpose of the study is to demonstrate "noninferiority" or "equivalence" to a proven treatment.[7] If the
experimental drug is equivalent to or better than the proven treatment, the study is considered positive. If the experimental drug is less effective then the proven treatment, the study is considered
negative.[7]

Results

Two companies providing the largest number of studies were Eli Lilly and GlaxoSmithKline (GSK); an overall summary of our results is shown in Table 1 . We then focused on the results provided
for the agent with the largest number of negative studies available, lamotrigine.

Table 1. Studies of Drugs on Bipolar Disorder on Pharmaceutical Industry Web Sites

# of
studies
on
company # of # of
Web site # of previously previously
If limited data on company Type of or previously published unpublished
Ease of Web site, findings on information PHRMA published negative negative
Company Drug Web site visited navigation Results www.clinicalstudyresults.org provided Web site studies studies studies

2 de 6 25/07/2009 10:38 a.m.


Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.com/viewarticle/579046_print

Abbott Depakote www.abbott.com Link to No data 1 unpublished positive study Only title of 1 0 0 0
(divalproex "Depakote"; link to for Depakote ER in acute study
[38]
sodium) "Professionals"; mania ; no data provided.
link to "Proven No reference to 2 previously
Efficacy." No published positive studies in
[39, 40]
further data. acute mania, and a
[41]
failed maintenance study.
AstraZeneca Seroquel www.astrazeneca.com Link to 4 in acute NA Full protocol 6 5 0 1
(quetiapine) "AstraZeneca-US"; mania with
Link to "Products"; reported, 3 detailed
Link to "Seroquel"; positive have summary of
Link to "Healthcare been results.
professionals." No published, Mean ± SD
[42-44]
further data. and 1 length 8.6 ±
negative 1.1 pages
unpublished (range
study in acute 7-10)
[45]
mania; 1
positive
published
study in acute
bipolar
[46]
depression
Bristol-Myers Abilify www.bms.com Link to "Clinical 5 studies in No titles or data. Titles of 5 2 0 1
Squibb (aripiprazole) trials disclosure"; acute mania, studies only
Link to "Clinical bipolar No reference to 2 previously
trials registry"; depression, published positive studies.
[47,48]
Link to or mania cited
"Therapeutic by titles and
areas"; Link to listed as
"Psychiatric "Recruiting"
disorders"; with no
further
information; 3
studies cited
as "no longer
recruiting"
and 1 as
"completed."
No citations
provided.

Eli Lilly Zyprexa www.elililly.com Link to "Products"; 6 studies of NA Full protocol 10 9 1 0


(olanzapine) link to "Lilly clinical acute mania, with
trials"; link to 3 studies of detailed
"Trials results by relapse summary of
product"; link to prevention, all results.
"Zyprexa" positive Mean ± SD
published length 15.6
studies[49-57] ± 8.0 pages
(range
6-28)

Eli Lilly Symbiax www.elililly.com Link to "Products"; 1 positive NA Full protocol 1 1 0 0


(olanzapine- link to "Lilly clinical study in acute with
fluoxetine trials"; link to bipolar detailed
[58]
combination) "Trials results by depression summary of
product"; link to results.
"Symbiax" Length 16
pages
GSK Lamictal www.gsk.com Link to "Clinical See Table 2 NA See Table 2 9 2 2 5
(lamotrigine) trial register"; link
to "Lamotrigine"
Janssen Risperdal www.janssen.com Link to "Our No data No titles or data. No reference No titles or 0 4 1 0
(risperidone) products"; link to to four previously published data
"Risperdal"; link to positive studies in acute mania,
[59-62]
"Risperdal for or one previously
bipolar mania" published negative but
underpowered study in acute
[63]
bipolar depression
Pfizer Geodon www.pfizer.com Link to "Medicines One efficacy 2 positive studies in acute Full protocol 2 2 0 0
(ziprasidone) and products"; link graph from 1 mania, 1 published [64] and 1 with
[65]
to "Geodon"; link published unpublished. No reference detailed
to "For healthcare study to another positive published summary of
provided[64]
[66]
professionals"; link acute mania trial results.
to "Clinical trial Mean ± SD
data"; link to length 7.0 ±
"Geodon for 2.0 pages
bipolar mania and (range 5-9)
mixed episodes"

Examining the Lamotrigine Data

Of major US pharmaceutical companies, so far only GSK has provided data on unpublished negative studies with results that were unfavorable to their product lamotrigine (Lamictal) ( Table 2 ).

Table 2. Published and Unpublished Randomized Clinical Trials of Lamotrigine in Bipolar Disorder

Duration
Scale Outcome Result Published
Study Diagnosis Design N (wks)

3 de 6 25/07/2009 10:38 a.m.


Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.com/viewarticle/579046_print

SCAA20 SCAA2008 Mania LTG vs Li vs Pla 216 3 MRS LTG -9.3 ± 10.9 Failed* No
Li -10.7 ± 11.6
Pla -9.5 ± 10.5
SCAA2009 Mania LTG vs Li vs Pla 229 6 MRS LTG -11.6 ± 14.0 Negative** No
Li -15.6 ± 13.0
Pla -11.4 ± 12.3
SCAA2010 Bipolar depression LTG vs Pla 206 10 HDRS LTG -10.6 ± 8.3 Negative*** No
Pla -10.2 ± 8.1
SCA40910 Bipolar depression LTG vs Pla 257 8 MADRS LTG -12.2 Negative*** No
Pla -11.2
SDs not provided
[25]
SCAB2001 Bipolar depression LTG vs Pla 195 7 HDRS LTG (200 mg/d) -10.5 ± 8.1 (P = .08) Negative*** Yes
LTG (50 mg/d) -9.3 ± 8.9 (P= .24)
Pla -7.8 ± 7.9
SCAB2005 Rapid cycling LTG vs Pla 137 32 TIME Median survival time Negative*** No
LTG 142 days
Pla 133 days
P = .73
[24]
SCAA2012 Rapid cycling LTG vs Pla 182 34 TIME Median survival time Negative*** Yes
LTG 126 days
Pla 79 days
P = .18
[22]
SCAB2003 Prophylaxis LTG vs Li vs Pla 463 72 TIME Median survival time Positive Yes
LTG 200 days
Li 170 days
Pla 93 days
P = .029 for both Li and LTG

SCAB2006 Prophylaxis LTG vs Li vs Pla 175 72 TIME Median survival time Positive Yes[23]
LTG 141days
Li 292 days
Pla 85 days
P = .02 for LTG
P = .003 for Li

Li=lithium; LTG=lamotrigine; Pla = placebo; TIME = time to Intervention with psychotropic


medications due to full relapse or initiation of relapse into mood episodes; MRS = Mania Rating
Scale from SADS-C; HDRS = Hamilton Depression Rating Scale; MADRS = Montgomery Asberg
Depression Rating Scale
* Lamotrigine and lithium (active control) were equivalent to placebo, thus no information for or against
lamotrigine efficacy can be concluded.
** Lamotrigine was equivalent to placebo but lithium was more effective than placebo.
*** Lamotrigine was equivalent to placebo in an adequately powered study to demonstrate modest
effect sizes.

This was not a voluntary act but rather due to legal judgment brought by the state of New York after a lawsuit about paroxetine use in children.[21] Of the 9 studies with lamotrigine in bipolar disorder
provided by the GSK Web site, 2 were positive and published, and supported the company's success in securing an FDA-approved indication for lamotrigine for delay of relapse in the long-term
treatment of bipolar disorder patients.[22,23] Two negative studies have been published, 1 in rapid-cycling[24] and another in acute bipolar depression,[25] but both published versions emphasize
positive secondary outcomes as opposed to the negative primary outcomes. A negative study in rapid cycling has not been published in detail (GW611), nor have 2 negative randomized studies in
acute bipolar depression (GW 40910 and GW 603), or 2 negative randomized trials in acute mania (GW609 and GW 610). However, all of these negative studies are reported at the company Web
site, which also refers to a publication[26] that briefly summarizes results from the above 5 negative studies. However, that publication provides little actual data from these negative studies; the
results are much more fully provided on their Web site.

Recently, using meta-analysis, academic investigators have published the results of 5 negative studies with lamotrigine in acute bipolar depression in more detail, confirming lack of benefit for
primary outcomes.[27] When pooling those 5 studies to produce a large sample of over 2000 subjects, a small effect size of depressive symptom benefit was statistically significant. However, more
benefit was seen in a subgroup analysis of those with high severity of depressive symptoms.[27]

Discussion

Given the above analysis, it still appears that negative outcomes, instead of being seen as important results in their own right, are treated by the pharmaceutical industry and many academic authors
as if they represent signets, putting a seal on all further discussion, thus needing to be suppressed or explained away. Even though GSK has now made the studies available, the information has not
been widely appreciated by the medical community.

The clinical relevance of the specific results with lamotrigine that are available through the GSK Web site is not insignificant. Two non-industry-funded studies found some benefit with lamotrigine in
acute bipolar depression (1 published[28] and another recent one not yet published).[29] Yet the unpublished negative studies described here are needed to put such positive studies in context.
Many clinicians and academics widely view lamotrigine as an effective treatment for, colloquially, "bipolar depression,"[30] even though the entire literature is less consistent on this point than many
clinicians and academics appear to assume. This impression has been furthered by the selective publishing of one of the RCTs[25] with a positive secondary outcome on Montgomery Asberg
Depression Rating Scale without emphasizing its negative outcome on the study's primary outcome on Hamilton Depression Rating Scale. Further, numerous review papers of lamotrigine in bipolar
disorder cite the single published study as evidence of benefit in acute bipolar depression, but make no mention of the unpublished studies.[30-32] This problem takes nothing away from the
evidence of lamotrigine's benefit in prophylaxis of bipolar disorder, particularly in prevention of depressive episodes, although it should be noted that the benefits seen in those prophylaxis studies
are limited to patients who initially tolerated and appeared to respond to lamotrigine for acute mood episodes. But preventive benefit does not necessarily translate to acute efficacy, or vice
versa.[33] Clinicians must learn to distinguish treatment of acute bipolar depression from its prevention. The lamotrigine data, positive and negative, could have been an important means of providing
empirical evidence of the importance of this distinction.

The importance of academic access to such unpublished data can hardly be underestimated. For instance, the published study of lamotrigine in rapid cycling bipolar disorder is conservatively
reported: the negative result in the primary outcome is acknowledged in the abstract, and the benefit in a secondary outcome in type II bipolar disorder may be clinically plausible and important.
However, despite this acceptable presentation of this study, the nonpublication of the second RCT, where there was no indication at all of any benefit in type II rapid cycling bipolar disorder, leaves
a mistaken impression in the published literature that lamotrigine is likely effective in that population. One out of 1 positive RCTs provides a different context than 1/2 positive RCTs. Instead,
post-hoc exploratory analyses of the unpublished data are published, which, after extensive data analysis, find some possible benefit (somewhat more euthymia in lamotrigine-treated patients vs
placebo utilizing a secondary outcome measure, the Life Chart Methodology).[34] While these exploratory analyses might be relevant, and even correct, the nonpublication of the straightforward
findings of the original RCT leads to a distorted context whereby the psychiatric literature overestimates the benefit of the drug.

Further, it is well known that systematic reviews, especially meta-analyses, are vulnerable to major biases if negative or failed trials showing statistical nonseparation of a drug vs placebo or an active
comparator are not available for analysis.[4,35] Further, narrative reviews of agents for bipolar disorder will provide the false impression that certain agents, such as lamotrigine, have been
consistently effective whenever they were studied, since positive studies are evidently more likely to be reported at Web sites or in published articles. The practice of burying negative data in
infrequently read review papers seems to be one approach to "publishing" such data, as exemplified by the single GSK-sponsored review paper which briefly summarized 5 negative studies with

4 de 6 25/07/2009 10:38 a.m.


Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.com/viewarticle/579046_print

limited detail[26]; yet this approach is not likely to provide adequate information for clinicians and researchers. Even when the negative studies are made available in more detail, as with a recent
meta-analysis of 5 negative acute bipolar depression studies with lamotrigine,[27] that kind of analysis should not replace earlier availability of each specific study. Further, since meta-analysis is an
observational data analytic exercise, it too is not definitive, and is open to differing interpretations.[36] Too often, it can take the form of "statistical alchemy,"[37] whereby huge samples provide
statistical significance to clinically meaningless differences. There is some danger of this kind of interpretation of the recent lamotrigine meta-analysis.[27]

Attention to publishing negative RCTs in a straightforward manner might be less necessary if clinicians were more critical readers of the research literature. However, many clinicians appear unable
to exercise methodological critique in their evaluation of papers, thus not sufficiently realizing, for instance, that the 2 main published studies of lamotrigine in acute bipolar depression needed to be
interpreted with much caution (one used a crossover design,[28] and the other emphasized a positive secondary outcome[25]). Thus, publishing negative data, though an improvement on the status
quo, will not be a panacea; clinicians will still need more training in critically interpreting research.

The clinical relevance of the lamotrigine studies is notable: Taking the negative outcomes into account, as of now, one might say that this agent is reasonably effective in maintenance treatment of
bipolar disorder, particularly in prevention of depression, among patients who initially tolerate and may benefit from acute lamotrigine treatment. It is proven ineffective in acute mania, rapid cycling,
and acute bipolar depression. Exploratory analyses suggest that a small effect size of benefit might occur in some patients with bipolar depression,[27] perhaps among those more severely ill,[27]
and the hypothesis of possible benefit in type II rapid cycling bipolar disorder was raised by one study but disconfirmed by another. This context of where the drug is effective, and where it is not, is
vital for scientifically valid and ethically honest clinical practice and research.

Conclusions

The pharmaceutical industry is not routinely making data from negative studies available through the published scientific literature or in available Internet sources. In the case of bipolar disorder, the
negative unpublished data made available on lamotrigine provide an important context for clinical practice and research.

References

1. Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA.
2002;287:2847-2850. Abstract
2. Rennie D, Flanagin A. Publication bias. The triumph of hope over experience. JAMA. 1992;267:411-412. Abstract
3. Dickersin K. The existence of publication bias and risk factors for its occurrence. Jama. 1990;263:1385-1389. Abstract
4. Gilbody S, House A. Publication bias and meta-analysis. Br J Psychiatry. 1995;167:266.
5. Koren G, Klein N. Bias against negative studies in newspaper reports of medical research. JAMA. 1991;266:1824-1826. Abstract
6. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry.
2005;162:1957-1960. Abstract
7. Hauck WW, Anderson S. A proposal for interpreting and reporting negative studies. Stat Med. 1986;5:203-209. Abstract
8. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med. 1986;1:155-158. Abstract
9. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565-568.
Abstract
10. Roth D, Boyle E, Beer D, Malik A, deBruyn J. Depressing research. Lancet. 2004;363:2087.
11. Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can J Psychiatry.
2004;49:601-606. Abstract
12. Finucane TE, Boult CE. Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. Am J Med. 2004;117:842-845. Abstract
13. Charatan F. Merck to pay $58m in settlement over rofecoxib advertising. BMJ. 2008;336:1208-1209.
14. Frazier KC. The lessons of Vioxx. N Engl J Med. 2005;353:1420-1421; author reply 1420-1421.
15. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007;4:e134.
16. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9:559-568. Abstract
17. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260. Abstract
18. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York: Springer-Verlag; 1998.
19. Rothman K, Greenland S. Modern epidemiology. Philadelphia, Pa: Lippincott-Raven; 1998.
20. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med.
2002;21:2917-2930. Abstract
21. Gibson L. GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ. 2004;328:1513.
22. Calabrese J, Bowden C, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin
Psychiatry. 2003;64:1013-1024. Abstract
23. Bowden C, Calabrese J, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
Arch Gen Psychiatry. 2003;60:392-400. Abstract
24. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin
Psychiatry. 2000;61:841-850. Abstract
25. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.
Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79-88. Abstract
26. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63:2029-2050. Abstract
27. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord.
2008;10:323-333. Abstract
28. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607-614.
Abstract
29. Nolen W. Treatment of Bipolar Depression. Paper presented at the 7th International Conference on Bipolar Disorders; June 7-9, 2007; Pittsburgh, Pennsylvania.
30. Bowden CL, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol. 1999;9(Suppl 4):S113-117. Abstract
31. Keck PE Jr, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry. 2003;53:671-679. Abstract
32. Keck PE Jr, McElroy SL. New approaches in managing bipolar depression. J Clin Psychiatry. 2003;64(Suppl 1):13-18. Abstract
33. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-433. Abstract
34. Goldberg JF, Bowden CL, Calabrese JR, et al. Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. Biol
Psychiatry. 2008;63:125-130. Abstract
35. Solomon P, Hutton J. Meta-analysis, overviews and publication bias. Stat Methods Med Res. 2001;10:245-250. Abstract
36. Ghaemi SN, Soldani F. Meta-analysis of observational studies: the case of rapid-cycling bipolar disorder. Acta Psychiatr Scand. 2003;108:1-3. Abstract
37. Feinstein AR. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol. 1995;48:71-79. Abstract
38. Abbott. Protocol No. M02540: A 21-Day, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Depakote ER in the Treatment of the Manic Phase of
Bipolar Disorder. 2006.
39. Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918-924. Abstract
40. Pope JG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68. Abstract
41. Bowden C, Calabrese J, McElroy S, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry.
2000;57:481-489. Abstract
42. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord.
2004;6:213-223. Abstract
43. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-
controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585. Abstract
44. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin
Psychiatry. 2005;66:111-121. Abstract
45. AstraZeneca. Protocol No. 5077IL/0100: An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SEROQUEL (Quetiapine
Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania. 2006.
46. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry.
2005;162:1351-1360. Abstract
47. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry.
2003;160:1651-1658. Abstract
48. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry.

5 de 6 25/07/2009 10:38 a.m.


Publication Bias and the Pharmaceutical Industry: Lamotrigine and Bipo... http://www.medscape.com/viewarticle/579046_print

2005;187:235-242. Abstract
49. Tohen M, Sanger T, McElroy S, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702-709. Abstract
50. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry.
2000;57:841-849. Abstract
51. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017. Abstract
52. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium
monotherapy. Arch Gen Psychiatry. 2002;59:62-69. Abstract
53. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J
Psychiatry. 2005;162:1281-1290. Abstract
54. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry.
2003;160:1263-1271. Abstract
55. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with
olanzapine. Am J Psychiatry. 2006;163:247-256. Abstract
56. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry.
2003;60:1218-1226. Abstract
57. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry.
2004;184:337-345. Abstract
58. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079-1088.
Abstract
59. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-
controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154. Abstract
60. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled
trial. Br J Psychiatry. 2003;182:141-147. Abstract
61. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
Abstract
62. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a
9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84. Abstract
63. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65:1715-1719. Abstract
64. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J
Psychiatry. 2003;160:741-748. Abstract
65. Pfizer. Protocol No. A1281052: A phase III, randomized, placebo-controlled, double-dummy study evaluating the safety and efficacy of oral ziprasidone vs. haloperidol and placebo in
in-patients with an acute manic episode. 2006.
66. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol.
2005;25:301-310. Abstract

Authors and Disclosures


S. Nassir Ghaemi, MD, Tufts Medical Center, Boston, Massachusetts
Author's email: nghaemi@tuftsmedicalcenter.org

Arshia A. Shirzadi, DO, Orange County Health Care Agency, Alcohol and Substance Abuse Services, Santa Ana, California

Megan Filkowski, BA, Emory University School of Medicine, Atlanta, Georgia

Disclosure: Dr. Ghaemi has disclosed the following relevant financial relationships in addition to his employment: GlaxoSmithKline and Astra Zeneca (speakers bureaus); Pfizer (research grants).

Disclosure: Dr. Shirzadi has disclosed no relevant financial relationships in addition to his employment.

Disclosure: Ms. Filkowski has disclosed no relevant financial relationships in addition to her employment.

Medscape J Med. 2008;10(9):211 © 2008 Medscape

6 de 6 25/07/2009 10:38 a.m.